A First in Human Study of STT-5058, an Antibody That Binds ApoC3

Summary

A First in Human Study of STT-5058, an Antibody That Binds ApoC3, investigating single and multiple ascending intravenous doses and ascending subcutaneous doses of STT-5058 in otherwise healthy volunteers with elevated triglyceride levels

Timeline

Start

2020-05-26

Primary completion

2022-12-23

Completion

2022-12-23

Outcome

Outcome not reported

Stopped (Enrollment): “recruitment failure”

Drugs

Indications